机译:SARS-COV-2 MRN通过原型病原体制备使能实现疫苗设计
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Moderna Inc;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Moderna Inc;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Department of Microbiology and Immunology School of Medicine University of North Carolina at Chapel Hill;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
National Institute of Allergy and Infectious Diseases National Institutes of Health;
National Institute of Allergy and Infectious Diseases National Institutes of Health;
National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health|Institute for Biomedical Sciences George Washington University;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Moderna Inc;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill;
Department of Pediatrics Vanderbilt University Medical Center;
Department of Molecular Biosciences University of Texas at Austin;
Department of Molecular Biosciences University of Texas at Austin;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Moderna Inc;
Moderna Inc;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Biostatistics Research Branch Division of Clinical Research National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Department of Molecular Biosciences University of Texas at Austin;
Department of Pediatrics Vanderbilt University Medical Center;
Department of Pediatrics Vanderbilt University Medical Center;
National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
Department of Epidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill|Department of Microbiology and Immunology School of Medicine University of North Carolina at Chapel Hill;
Moderna Inc;
Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health;
机译:从埃博拉疫苗经验中施用课程,对SARS-COV-2和其他流行病病原体
机译:在线原型数据库设计模板,用于低层建筑的风分析/设计
机译:基于结构的基于标签的纯化和工艺生物素化的设计能够精简SARS-COV-2穗分子探针的开发
机译:用于检测上呼吸道病原体的多重PCR CMOS Biochip,包括SARS-COV-2
机译:猪圆环病毒2(PCV2)疫苗的免疫原性评估:原型疫苗和λ展示疫苗。
机译:利用转基因抗原表达细胞作为免疫原性和佐剂抗SARS-CoV-2病毒原型的新型诱饵细胞疫苗策略
机译:新的诱饵细胞疫苗策略利用转基因抗原表达细胞作为免疫施用者和疫苗原型中的佐剂,对抗SARS-COV-2病毒